IBDEI222 ; ; 04-FEB-2020
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,32806,1,4,0)
;;=4^H40.61X0
;;^UTILITY(U,$J,358.3,32806,2)
;;=^5005906
;;^UTILITY(U,$J,358.3,32807,0)
;;=H40.61X1^^128^1670^48
;;^UTILITY(U,$J,358.3,32807,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,32807,1,3,0)
;;=3^GLU 2nd to Drugs,OD,Mild Stage
;;^UTILITY(U,$J,358.3,32807,1,4,0)
;;=4^H40.61X1
;;^UTILITY(U,$J,358.3,32807,2)
;;=^5005907
;;^UTILITY(U,$J,358.3,32808,0)
;;=H40.61X2^^128^1670^49
;;^UTILITY(U,$J,358.3,32808,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,32808,1,3,0)
;;=3^GLU 2nd to Drugs,OD,Moderate Stage
;;^UTILITY(U,$J,358.3,32808,1,4,0)
;;=4^H40.61X2
;;^UTILITY(U,$J,358.3,32808,2)
;;=^5005908
;;^UTILITY(U,$J,358.3,32809,0)
;;=H40.61X3^^128^1670^50
;;^UTILITY(U,$J,358.3,32809,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,32809,1,3,0)
;;=3^GLU 2nd to Drugs,OD,Severe Stage
;;^UTILITY(U,$J,358.3,32809,1,4,0)
;;=4^H40.61X3
;;^UTILITY(U,$J,358.3,32809,2)
;;=^5133509
;;^UTILITY(U,$J,358.3,32810,0)
;;=H40.61X4^^128^1670^51
;;^UTILITY(U,$J,358.3,32810,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,32810,1,3,0)
;;=3^GLU 2nd to Drugs,OD,Indeterminate Stage
;;^UTILITY(U,$J,358.3,32810,1,4,0)
;;=4^H40.61X4
;;^UTILITY(U,$J,358.3,32810,2)
;;=^5005909
;;^UTILITY(U,$J,358.3,32811,0)
;;=H40.813^^128^1670^64
;;^UTILITY(U,$J,358.3,32811,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,32811,1,3,0)
;;=3^GLC w/ Increased Episcleral Venous Pressure,OU
;;^UTILITY(U,$J,358.3,32811,1,4,0)
;;=4^H40.813
;;^UTILITY(U,$J,358.3,32811,2)
;;=^5005921
;;^UTILITY(U,$J,358.3,32812,0)
;;=H40.811^^128^1670^62
;;^UTILITY(U,$J,358.3,32812,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,32812,1,3,0)
;;=3^GLC w/ Increased Episcleral Venous Pressure,OD
;;^UTILITY(U,$J,358.3,32812,1,4,0)
;;=4^H40.811
;;^UTILITY(U,$J,358.3,32812,2)
;;=^5005919
;;^UTILITY(U,$J,358.3,32813,0)
;;=H40.812^^128^1670^63
;;^UTILITY(U,$J,358.3,32813,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,32813,1,3,0)
;;=3^GLC w/ Increased Episcleral Venous Pressure,OS
;;^UTILITY(U,$J,358.3,32813,1,4,0)
;;=4^H40.812
;;^UTILITY(U,$J,358.3,32813,2)
;;=^5005920
;;^UTILITY(U,$J,358.3,32814,0)
;;=H40.823^^128^1670^67
;;^UTILITY(U,$J,358.3,32814,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,32814,1,3,0)
;;=3^Hypersecretion GLC,OU
;;^UTILITY(U,$J,358.3,32814,1,4,0)
;;=4^H40.823
;;^UTILITY(U,$J,358.3,32814,2)
;;=^5005925
;;^UTILITY(U,$J,358.3,32815,0)
;;=H40.821^^128^1670^65
;;^UTILITY(U,$J,358.3,32815,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,32815,1,3,0)
;;=3^Hypersecretion GLC,OD
;;^UTILITY(U,$J,358.3,32815,1,4,0)
;;=4^H40.821
;;^UTILITY(U,$J,358.3,32815,2)
;;=^5005923
;;^UTILITY(U,$J,358.3,32816,0)
;;=H40.822^^128^1670^66
;;^UTILITY(U,$J,358.3,32816,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,32816,1,3,0)
;;=3^Hypersecretion GLC,OS
;;^UTILITY(U,$J,358.3,32816,1,4,0)
;;=4^H40.822
;;^UTILITY(U,$J,358.3,32816,2)
;;=^5005924
;;^UTILITY(U,$J,358.3,32817,0)
;;=H40.43X0^^128^1670^27
;;^UTILITY(U,$J,358.3,32817,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,32817,1,3,0)
;;=3^Inflam GLC,OU,Stage Unspec
;;^UTILITY(U,$J,358.3,32817,1,4,0)
;;=4^H40.43X0
;;^UTILITY(U,$J,358.3,32817,2)
;;=^5005878
;;^UTILITY(U,$J,358.3,32818,0)
;;=H40.43X1^^128^1670^28
;;^UTILITY(U,$J,358.3,32818,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,32818,1,3,0)
;;=3^Inflam GLC,OU,Mild Stage
;;^UTILITY(U,$J,358.3,32818,1,4,0)
;;=4^H40.43X1
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI222 3791 printed Sep 23, 2025@19:56:16 Page 2
IBDEI222 ; ; 04-FEB-2020
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,32806,1,4,0)
+2 ;;=4^H40.61X0
+3 ;;^UTILITY(U,$J,358.3,32806,2)
+4 ;;=^5005906
+5 ;;^UTILITY(U,$J,358.3,32807,0)
+6 ;;=H40.61X1^^128^1670^48
+7 ;;^UTILITY(U,$J,358.3,32807,1,0)
+8 ;;=^358.31IA^4^2
+9 ;;^UTILITY(U,$J,358.3,32807,1,3,0)
+10 ;;=3^GLU 2nd to Drugs,OD,Mild Stage
+11 ;;^UTILITY(U,$J,358.3,32807,1,4,0)
+12 ;;=4^H40.61X1
+13 ;;^UTILITY(U,$J,358.3,32807,2)
+14 ;;=^5005907
+15 ;;^UTILITY(U,$J,358.3,32808,0)
+16 ;;=H40.61X2^^128^1670^49
+17 ;;^UTILITY(U,$J,358.3,32808,1,0)
+18 ;;=^358.31IA^4^2
+19 ;;^UTILITY(U,$J,358.3,32808,1,3,0)
+20 ;;=3^GLU 2nd to Drugs,OD,Moderate Stage
+21 ;;^UTILITY(U,$J,358.3,32808,1,4,0)
+22 ;;=4^H40.61X2
+23 ;;^UTILITY(U,$J,358.3,32808,2)
+24 ;;=^5005908
+25 ;;^UTILITY(U,$J,358.3,32809,0)
+26 ;;=H40.61X3^^128^1670^50
+27 ;;^UTILITY(U,$J,358.3,32809,1,0)
+28 ;;=^358.31IA^4^2
+29 ;;^UTILITY(U,$J,358.3,32809,1,3,0)
+30 ;;=3^GLU 2nd to Drugs,OD,Severe Stage
+31 ;;^UTILITY(U,$J,358.3,32809,1,4,0)
+32 ;;=4^H40.61X3
+33 ;;^UTILITY(U,$J,358.3,32809,2)
+34 ;;=^5133509
+35 ;;^UTILITY(U,$J,358.3,32810,0)
+36 ;;=H40.61X4^^128^1670^51
+37 ;;^UTILITY(U,$J,358.3,32810,1,0)
+38 ;;=^358.31IA^4^2
+39 ;;^UTILITY(U,$J,358.3,32810,1,3,0)
+40 ;;=3^GLU 2nd to Drugs,OD,Indeterminate Stage
+41 ;;^UTILITY(U,$J,358.3,32810,1,4,0)
+42 ;;=4^H40.61X4
+43 ;;^UTILITY(U,$J,358.3,32810,2)
+44 ;;=^5005909
+45 ;;^UTILITY(U,$J,358.3,32811,0)
+46 ;;=H40.813^^128^1670^64
+47 ;;^UTILITY(U,$J,358.3,32811,1,0)
+48 ;;=^358.31IA^4^2
+49 ;;^UTILITY(U,$J,358.3,32811,1,3,0)
+50 ;;=3^GLC w/ Increased Episcleral Venous Pressure,OU
+51 ;;^UTILITY(U,$J,358.3,32811,1,4,0)
+52 ;;=4^H40.813
+53 ;;^UTILITY(U,$J,358.3,32811,2)
+54 ;;=^5005921
+55 ;;^UTILITY(U,$J,358.3,32812,0)
+56 ;;=H40.811^^128^1670^62
+57 ;;^UTILITY(U,$J,358.3,32812,1,0)
+58 ;;=^358.31IA^4^2
+59 ;;^UTILITY(U,$J,358.3,32812,1,3,0)
+60 ;;=3^GLC w/ Increased Episcleral Venous Pressure,OD
+61 ;;^UTILITY(U,$J,358.3,32812,1,4,0)
+62 ;;=4^H40.811
+63 ;;^UTILITY(U,$J,358.3,32812,2)
+64 ;;=^5005919
+65 ;;^UTILITY(U,$J,358.3,32813,0)
+66 ;;=H40.812^^128^1670^63
+67 ;;^UTILITY(U,$J,358.3,32813,1,0)
+68 ;;=^358.31IA^4^2
+69 ;;^UTILITY(U,$J,358.3,32813,1,3,0)
+70 ;;=3^GLC w/ Increased Episcleral Venous Pressure,OS
+71 ;;^UTILITY(U,$J,358.3,32813,1,4,0)
+72 ;;=4^H40.812
+73 ;;^UTILITY(U,$J,358.3,32813,2)
+74 ;;=^5005920
+75 ;;^UTILITY(U,$J,358.3,32814,0)
+76 ;;=H40.823^^128^1670^67
+77 ;;^UTILITY(U,$J,358.3,32814,1,0)
+78 ;;=^358.31IA^4^2
+79 ;;^UTILITY(U,$J,358.3,32814,1,3,0)
+80 ;;=3^Hypersecretion GLC,OU
+81 ;;^UTILITY(U,$J,358.3,32814,1,4,0)
+82 ;;=4^H40.823
+83 ;;^UTILITY(U,$J,358.3,32814,2)
+84 ;;=^5005925
+85 ;;^UTILITY(U,$J,358.3,32815,0)
+86 ;;=H40.821^^128^1670^65
+87 ;;^UTILITY(U,$J,358.3,32815,1,0)
+88 ;;=^358.31IA^4^2
+89 ;;^UTILITY(U,$J,358.3,32815,1,3,0)
+90 ;;=3^Hypersecretion GLC,OD
+91 ;;^UTILITY(U,$J,358.3,32815,1,4,0)
+92 ;;=4^H40.821
+93 ;;^UTILITY(U,$J,358.3,32815,2)
+94 ;;=^5005923
+95 ;;^UTILITY(U,$J,358.3,32816,0)
+96 ;;=H40.822^^128^1670^66
+97 ;;^UTILITY(U,$J,358.3,32816,1,0)
+98 ;;=^358.31IA^4^2
+99 ;;^UTILITY(U,$J,358.3,32816,1,3,0)
+100 ;;=3^Hypersecretion GLC,OS
+101 ;;^UTILITY(U,$J,358.3,32816,1,4,0)
+102 ;;=4^H40.822
+103 ;;^UTILITY(U,$J,358.3,32816,2)
+104 ;;=^5005924
+105 ;;^UTILITY(U,$J,358.3,32817,0)
+106 ;;=H40.43X0^^128^1670^27
+107 ;;^UTILITY(U,$J,358.3,32817,1,0)
+108 ;;=^358.31IA^4^2
+109 ;;^UTILITY(U,$J,358.3,32817,1,3,0)
+110 ;;=3^Inflam GLC,OU,Stage Unspec
+111 ;;^UTILITY(U,$J,358.3,32817,1,4,0)
+112 ;;=4^H40.43X0
+113 ;;^UTILITY(U,$J,358.3,32817,2)
+114 ;;=^5005878
+115 ;;^UTILITY(U,$J,358.3,32818,0)
+116 ;;=H40.43X1^^128^1670^28
+117 ;;^UTILITY(U,$J,358.3,32818,1,0)
+118 ;;=^358.31IA^4^2
+119 ;;^UTILITY(U,$J,358.3,32818,1,3,0)
+120 ;;=3^Inflam GLC,OU,Mild Stage
+121 ;;^UTILITY(U,$J,358.3,32818,1,4,0)
+122 ;;=4^H40.43X1
